<?xml version='1.0' encoding='utf-8'?>
<document id="17965516"><sentence text="Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics."><entity charOffset="14-24" id="DDI-PubMed.17965516.s1.e0" text="tacrolimus" /><entity charOffset="26-31" id="DDI-PubMed.17965516.s1.e1" text="FK506" /><pair ddi="false" e1="DDI-PubMed.17965516.s1.e0" e2="DDI-PubMed.17965516.s1.e0" /><pair ddi="false" e1="DDI-PubMed.17965516.s1.e0" e2="DDI-PubMed.17965516.s1.e1" /></sentence><sentence text="Tacrolimus (FK506), an immunosuppressive drug, is co-medicated with multiple drugs under clinical conditions"><entity charOffset="12-16" id="DDI-PubMed.17965516.s2.e0" text="FK506" /></sentence><sentence text=" Tacrolimus is highly lipophilic and is excreted from the body after receiving extensive metabolism" /><sentence text=" Due to its narrow therapeutic window following organ transplantation, tacrolimus requires therapeutic drug monitoring by an enzyme immunoassay using the monoclonal antibody raised against tacrolimus" /><sentence text=" Therefore, metabolism studies including drug-drug interaction and metabolite identification studies are essential for the efficient development and clinically optimal usage of this drug" /><sentence text=" Tacrolimus was metabolized by the cytochrome P450 (CYP) 3A subfamily" /><sentence text=" Metabolic drug-drug interaction studies were conducted to provide information regarding the optimal usage of tacrolimus, and its metabolism was inhibited by known CYP3A inhibitors such as ketoconazole, cyclosporine A, and nifedipine"><entity charOffset="110-120" id="DDI-PubMed.17965516.s7.e0" text="tacrolimus" /><entity charOffset="189-201" id="DDI-PubMed.17965516.s7.e1" text="ketoconazole" /><entity charOffset="203-217" id="DDI-PubMed.17965516.s7.e2" text="cyclosporine A" /><entity charOffset="223-233" id="DDI-PubMed.17965516.s7.e3" text="nifedipine" /><pair ddi="false" e1="DDI-PubMed.17965516.s7.e0" e2="DDI-PubMed.17965516.s7.e0" /><pair ddi="false" e1="DDI-PubMed.17965516.s7.e0" e2="DDI-PubMed.17965516.s7.e1" /><pair ddi="false" e1="DDI-PubMed.17965516.s7.e0" e2="DDI-PubMed.17965516.s7.e2" /><pair ddi="false" e1="DDI-PubMed.17965516.s7.e0" e2="DDI-PubMed.17965516.s7.e3" /><pair ddi="false" e1="DDI-PubMed.17965516.s7.e1" e2="DDI-PubMed.17965516.s7.e1" /><pair ddi="false" e1="DDI-PubMed.17965516.s7.e1" e2="DDI-PubMed.17965516.s7.e2" /><pair ddi="false" e1="DDI-PubMed.17965516.s7.e1" e2="DDI-PubMed.17965516.s7.e3" /><pair ddi="false" e1="DDI-PubMed.17965516.s7.e2" e2="DDI-PubMed.17965516.s7.e2" /><pair ddi="false" e1="DDI-PubMed.17965516.s7.e2" e2="DDI-PubMed.17965516.s7.e3" /></sentence><sentence text=" Recent reports on clinical pharmacokinetics indicate that dose levels of tacrolimus need to be adjusted in transplant patients with CYP3A5 polymorphism"><entity charOffset="74-84" id="DDI-PubMed.17965516.s8.e0" text="tacrolimus" /></sentence><sentence text="" /></document>